Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
|Videos|February 21, 2019
Novel Treatments for HIV Currently in Development
Author(s)Contagion® Editorial Staff
Paul Sax, MD, discusses treatments for HIV that are currently in development.
Advertisement
Segment Description: Paul Edward Sax, MD, clinical director, professor of medicine, Harvard Medical School; clinical director of the Division of Infectious Diseases at Brigham and Women’s Hospital, discusses treatments for HIV that are currently in development.
Contagion®: What are some novel treatments for HIV in phase 3? What makes them unique options?
Dr. Sax: “A very interesting new approach to managing patients with HIV, who already are successfully treated, is long-acting injectable treatments. Currently, in phase 3 is a combination injectable treatment of cabotegravir and rilpivirine to be given every 4 weeks as an injection. This is really sort of a transformative idea — it's a way of treating HIV without taking a pill every day.
The reason why it's so interesting is because even though we right now have wonderful treatments — just a single pill a day that can successfully treat HIV in essentially everybody – there are some people who really don't like taking pills. And, there are many people who say that taking a pill every day reminds them of their diagnosis and reminds them of the stigma associated with HIV and so they're very eagerly awaiting this new approach to treatment.”
Advertisement
Related to this article
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
The guidelines issued by the Department of Health and Human Services (HHS) have been updated with recent, evidence-based consensus of The Panel for the Use of Antiretroviral Agents in Adults and Adolescents.
Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Advertisement
Advertisement
Trending on Contagion Live
1
Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events
4
Asuptegravir Lowers HIV-1 RNA up to 2.36 Logs in Early Monotherapy
5